Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
This partnership marks a significant step for the Company towards establishing renewable energy power generation using hybrid open excess through solar and wind sources
PREVENAR offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine to help protect infants and children from the 20 serotypes responsible for the majority of currently circulating pneumococcal disease in the EU and globally
This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India
Combines biocompatibility, heat-resistance, transparency and durability
Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival
An accomplished R&D leader and champion of the application of AI to drug discovery
NEIAFMR to be developed as the national hub for folk medicine
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
Receives registration of Valganciclovir powder for oral solution in Germany
Subscribe To Our Newsletter & Stay Updated
